Gilead Licenses Obeldesivir to 127 Countries

Gilead licenses Obeldesivir royalty-free to 127 countries.

FDA regulators this week cleared two new treatment options for hard-to-manage chronic diseases: Novartis’s Cosentyx (secukinumab) for polymyalgia rheumatica, and Roche’s Wilserdly, combined with everolimus, for ESR1-mutated advanced breast cancer.

Both approvals rest on Phase III trial results, PharmExec reported.

The Cosentyx decision matters because polymyalgia rheumatica — an inflammatory condition causing shoulder and hip stiffness in adults over 50 — has long been treated almost entirely with corticosteroids.

Up to 40% of patients relapse on steroids within a year, according to the Phase III Replenish trial data cited by PharmExec. Secukinumab, an anti-IL-17 biologic, doubled the likelihood of sustained remission in that trial, making it the first and only anti-IL-17 biologic cleared for the disease.

In oncology, Roche’s Wilserdly won approval in combination with everolimus for ER-positive, HER2-negative breast cancer carrying an ESR1 mutation — a resistance mechanism that often emerges after years of hormone therapy. In the Phase III EvERA trial, the combination cut the risk of progression or death by 62% versus standard therapy.

The same week’s headlines carried a third signal about access to experimental medicine.

The deals, modeled on Gilead’s earlier remdesivir Covid-19 licenses, are designed to build manufacturing and supply capacity before the Ebo-pep trial, a partner-led Phase III field study, reports results.

Jaime McCoy, vice president of Gilead Patient Solutions, said the agreements reflect the company’s commitment to “preparing for future access while clinical research is ongoing.”

New Treatment Options for Polymyalgia Rheumatica and ESR1-Mutated Breast Cancer

  • Polymyalgia rheumatica patients have a steroid-free option. Cosentyx blocks an immune signaling protein (IL-17) that drives inflammation, offering an alternative for people who relapse on or cannot tolerate long-term steroids.
  • Wilserdly targets a specific mutation, not all breast cancers. It applies only to hormone-receptor-positive, HER2-negative cancers that have developed an ESR1 mutation — usually after prior hormone therapy stopped working.
  • Gilead’s licensing deal doesn’t make obeldesivir available yet. The antiviral is still investigational; the agreements prepare supply chains in case the ongoing Ebola prevention trial succeeds.

How the Two Approvals Work

Cosentyx’s mechanism of action is targeted immunomodulation. Secukinumab is a monoclonal antibody — a lab-made protein — that binds and neutralizes interleukin-17A, a cytokine (a chemical messenger of the immune system) implicated in the inflammation driving polymyalgia rheumatica.

The drug is already approved for psoriasis, psoriatic arthritis, and axial spondyloarthritis, so its long-term safety profile in other inflammatory diseases is established, though dosing and risk-benefit for polymyalgia rheumatica specifically follow the new indication’s labeling.

Wilserdly addresses acquired endocrine resistance. In ER-positive breast cancer, the estrogen receptor drives tumor growth; the ESR1 mutation alters that receptor so common endocrine therapies lose their grip. Pairing Wilserdly with everolimus, an mTOR inhibitor that slows cancer-cell growth signaling, attacked the pathway from two directions — and the EvERA trial’s 62% reduction in the risk of progression or death reflects that dual approach against standard therapy.

What the Trials Show, Side by Side

Therapy Disease Phase III Trial Headline Result
Cosentyx (secukinumab), Novartis Polymyalgia rheumatica Replenish Doubled likelihood of sustained remission; first anti-IL-17 biologic approved for the disease
Wilserdly + everolimus, Roche ER-positive, HER2-negative, ESR1-mutated advanced breast cancer EvERA 62% reduction in risk of progression or death vs. standard therapy
Obeldesivir, Gilead (investigational) Ebola Bundibugyo virus disease (post-exposure prophylaxis) Ebo-pep (ongoing) Licensed royalty-free in 127 countries pending trial results

Who Funded the Evidence

Both important trials were sponsored by the drugs' manufacturers: Novartis sponsored Replenish, and Roche sponsored EvERA. That is standard for Phase III registration trials, because only the license holder can fund the studies regulators require — but it means the efficacy data comes from companies with a direct commercial stake in the results.

Independent post-marketing surveillance and real-world evidence will be the checks on these findings. On the access side, Gilead’s licenses are explicitly royalty-free, which removes one financial barrier for generic manufacturers in the 127 covered countries.

Geography of Access

The FDA approvals apply to the United States; patients in Europe and the UK await parallel review by the European Medicines Agency and the UK’s MHRA before these indications become prescribable there.

The Gilead licensing agreements run the opposite direction geographically — they deliberately exclude high-income markets and concentrate on low- and lower-middle-income countries, including every African nation reporting cases in the current Ebola Bundibugyo outbreak, so that supply exists where the risk is highest if the trial confirms benefit.

Anti-IL-17 biologics such as secukinumab work by dampening part of the immune response, so patients with active infections — particularly tuberculosis — should not start therapy until those are treated, and anyone with a history of recurrent infections or inflammatory bowel disease should discuss the risks with their rheumatologist before starting.

Breast cancer patients should not request Wilserdly unless their tumor has been tested and confirmed ESR1-mutated; the approval does not extend to hormone-receptor-positive cancers without that mutation. Obeldesivir is not approved and cannot be prescribed outside clinical trials. Any patient on these therapies who develops signs of infection, unexplained breathlessness, or new or worsening symptoms should contact their treating physician promptly.

What Comes Next

The nearest dated milestone is the readout of the Ebo-pep trial, the partner-led Phase III field study of obeldesivir as Ebola post-exposure prophylaxis; Gilead’s licensing partners will scale manufacturing while that research continues, as Gilead Sciences describes the agreements as “preparing for future access while clinical research is ongoing.”

References

  • Pharmaceutical Executive (PharmExec), “Pharmaceutical Executive Daily” — reporting on the FDA approvals, Replenish and EvERA trial results, and Gilead’s obeldesivir licensing agreements
  • U.S. Food and Drug Administration — drug approval announcements for Cosentyx (secukinumab) and Wilserdly
  • Novartis — Phase III Replenish trial program in polymyalgia rheumatica
  • Roche — Phase III EvERA trial in ESR1-mutated advanced breast cancer
  • Gilead Sciences — voluntary licensing announcements for obeldesivir and the Ebo-pep study

Treatment decisions should be made with a qualified healthcare professional.

Photo of author

Health Desk

Health Desk at Archyde.

Irma P. Hall, ‘Soul Food’ and ‘Ladykillers’ Actress, Dies at 91

San José Fast-Track Restaurant Permitting Program Expands Citywide